Over the past 40 years, pulmonary arterial hypertension (PAH) has been transformed into a treatable chronic condition thanks to advances in vascular biology. The President’s Symposium at ATS 2026 Orlando offered expert-driven insights into PAH therapeutic pathways and future areas of investigation.

Pulmonary Clinical Core Curriculum Co-Chairs Erin Camac, DO, ATSF, and Josalyn Cho, MD, ATSF, previewed this year’s series, which will delve into pulmonary hypertension — an area of practice that has been rapidly evolving. The two sessions are scheduled from 2:15–3:45 p.m. on Tuesday and 11 a.m.–12:30 p.m. on Wednesday.